SharonAnnSavageMD

Summary

• Sharon A. Savage, M.D., is the Director of the Clinical Genetics Branch and Clinical Director of the Division of Cancer Epidemiology and Genetics at the National Cancer Institute (NCI). She received her MD from the University of Vermont College of Medicine, completed residency in Pediatrics at Children’s National Medical Center, Washington, DC, and fellowship in Pediatric Hematology-Oncology in the combined NCI-Johns Hopkins program.
  Dr. Savage's internationally recognized research program combines clinical, genetic, and epidemiologic studies to advance understanding of cancer etiology and improve the lives of individuals with complex cancer-prone disorders. Her work in inherited bone marrow failure syndromes has discovered numerous new genetic etiologies, advanced understanding of telomere biology, and provided unprecedented detailed clinical phenotype studies.
  Dr. Savage created the NCI’s clinical and genetic study of Li-Fraumeni syndrome (LFS), a cancer-prone disorder often caused by germline mutations in TP53, resulting in robust quantification of cancer risk, genotype-phenotype correlations, characterization of the LFS-associated malignancies and a robust pediatric and adult cancer-screening regimen.
  Known for her emphasis on international scientific collaboration, Dr. Savage established and co-leads the LFS Exploration (LiFE) research consortium, Clinical Care Consortium of Telomere-Associated Ailments (CCCTAA) and works closely with basic scientists to connect disease mechanisms with clinical manifestations.